RapidAI: Toward a Timeless Assessment of Stroke

article image

Time—whether ischemic stroke patients are treated within 6, 12, or 24 hours—isn’t the most telling variable affecting stroke outcomes. Every stroke is unique to the patient, and RapidAI is in the business of providing neuroimaging software that provides patient-relevant information to clinicians that have tough treatment decisions to make.

RapidAI Inc. has the most comprehensive suite of neuroimaging software for stroke—multiple modules of software that glean insights from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans—and its products have helped clinicians interpret more than two million imaging scans in 1800-plus hospitals in more than 60 countries. Its software for the automated analysis of images has advanced the evolution of stroke care, having been used even prior to the company’s incorporation to select and study patients in many of the landmark trials validating the role of endovascular thrombectomy and intravenous thrombolysis in ischemic stroke.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: